Tango Therapeutics
NASDAQ: TNGXBoston, US · Founded 2020 · Delaware corporation · 4 known investors
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
Founders & leadership
Tango Therapeutics was founded in 2020 by Alan Huang.
AH
Alan HuangFounder
AC
Adam CrystalExecutive
DB
Daniella BeckmanExecutive
DB
Douglas BarryNamed on SEC filing
AD
Aaron DavisNamed on SEC filing
Board
BW
KP
Kanishka PothulaBoard directorManaging Partner at Nextech Invest
LA
Lesley Ann CalhounBoard director
AB
Alexis BorisyBoard directorChairman at Nextech Invest
RH
JK
John KetchumBoard director
MP
Malte PetersBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$95M disclosed across 2 rounds · 2023–2025
▶$15MraisedOct 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedOct 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John KetchumDirector
- Barbara WeberExecutive Officer, Director
- Malte PetersDirector
- Kanishka PothulaDirector
- Lesley Ann CalhounDirector
- Mace RothenbergDirector
- Alexis BorisyDirector
- Adam CrystalExecutive Officer
- Daniella BeckmanExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80MraisedAug 2023 · 17 investors · PharmaceuticalsRule 506(b)
▶$80MraisedAug 2023 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lesley Ann CalhounDirector
- Adam CrystalExecutive Officer
- Douglas BarryExecutive Officer
- Mace RothenbergDirector
- Alexis BorisyDirector
- Alan HuangExecutive Officer
- Barbara WeberExecutive Officer, Director
- Daniella BeckmanExecutive Officer
- Malte PetersDirector
- Reid HuberDirector
- Aaron DavisDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Tango Therapeutics went on to found or lead other companies.
Competitors · 3
by search overlapTango Technology47 shared keywordsTango is a browser extension that automatically captures workflows and turns them into step-by-step how-to guides with screenshots and highlights, which teams can share, embed in knowledge bases, and turn into automations. It targets companies driving digital adoption across web-based tools such as CRM, ERP, and HRIS systems.
Tangoanalytics37 shared keywordsTango provides a software platform for managing commercial real estate portfolios across corporate, retail, and other enterprises. The platform covers site selection, lease management, energy and sustainability tracking, workplace optimization, and project coordination.
Tango Tango35 shared keywords
Companies competing with Tango Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tango Therapeutics do?
- Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
- Who founded Tango Therapeutics?
- Tango Therapeutics was founded by Alan Huang in 2020.
- Who are Tango Therapeutics's investors?
- Tango Therapeutics's investors include Foresite Capital, Nextech Invest, NSG Ventures, Third Rock Ventures.
- How much funding has Tango Therapeutics raised?
- Tango Therapeutics has disclosed $95M raised across 2 rounds.
- Where is Tango Therapeutics headquartered?
- Tango Therapeutics is headquartered in Boston, US.